Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (5y) (2014 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.89% |
| Mar 31, 2026 | 20.46% |
| Dec 31, 2025 | 125.04% |
| Sep 30, 2025 | 44.87% |
| Jun 30, 2025 | -10.08% |
| Mar 31, 2025 | 20.14% |
| Dec 31, 2024 | 20.90% |
| Sep 30, 2024 | 20.54% |
| Jun 30, 2024 | -6.80% |
| Mar 31, 2024 | -19.08% |
| Dec 31, 2023 | -33.41% |
| Sep 30, 2023 | 60.20% |
| Jun 30, 2023 | 16.14% |
| Mar 31, 2023 | 4.64% |
| Dec 31, 2022 | -19.82% |
| Sep 30, 2022 | 34.48% |
| Jun 30, 2022 | -26.69% |
| Mar 31, 2022 | -65.95% |
| Dec 31, 2021 | -66.49% |
| Sep 30, 2021 | 40.25% |